Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
Document Type
Journal Article
Publication Date
2-1-2018
Journal
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology
Volume
20
Issue
2
Inclusive Pages
359–369
DOI
10.1002/ejhf.937
Keywords
Angiotensin-Converting Enzyme Inhibitors; Canada; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Enalapril; Europe; Follow-Up Studies; Heart Failure; Humans; Stroke Volume; Survival Rate; Treatment Outcome; United States
APA Citation
Lam, P., Dooley, D., Fonarow, G., Butler, J., Bhatt, D., Filippatos, G., Deedwania, P., Forman, D., White, M., Fletcher, R., Arundel, C., Blackman, M., Adamopoulos, C., Kanonidis, I., Aban, I., Patel, K., Aronow, W., Allman, R., Anker, S., Pitt, B., & Ahmed, A. (2018). Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.. European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology, 20 (2). http://dx.doi.org/10.1002/ejhf.937
Peer Reviewed
1